Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 226

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 1
Chunk 226
---
 160,333 NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH130,284 74,716 Cash, cash equivalents and restricted cash at beginning of period561,380 332,359 Cash, cash equivalents and restricted cash at end of period$691,664 $407,075 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:Cash paid for federal income taxes$1,500 $— Property and equipment purchases in accounts payable and accrued expenses$14 $84 Issuance costs associated with the ATM agreement in accounts payable and accrued expenses$— $114 

The following table provides a reconciliation of the ending cash, cash equivalents and restricted cash as of each of the periods shown above:

JUNE 30,20252024Cash and cash equivalents$690,215 $405,863 Restricted cash1,449 1,212 Total cash, cash equivalents and restricted cash$691,664 $407,075 

See notes to condensed consolidated financial statements.

8

KEROS THERAPEUTICS, INC. 

Notes to Condensed Consolidated Financial Statements 

(Unaudited)

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION 

Keros Therapeutics, Inc. (“Keros” or the “Company”) was incorporated in 2015 as a Delaware corporation. Its principal offices are in Lexington, Massachusetts. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins. The Company's lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. The Company’s most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts (“cytopenias”), including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (“MDS”) and in patients with myelofibrosis.Since its inception in 2015, the Company has devoted the majority of its resources to business planning, research and development of its product candidates, including conducting clinical trials and preclinical studies, raising capital and recruiting management and technical staff to support these operations. To date, the Company has not generated any revenue from product sales as none of its product